These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 15947627)

  • 1. Changes in overactive bladder symptoms after discontinuation of successful 3-month treatment with an antimuscarinic agent: a prospective trial.
    Choo MS; Song C; Kim JH; Choi JB; Lee JY; Chung BS; Lee KS
    J Urol; 2005 Jul; 174(1):201-4. PubMed ID: 15947627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'.
    Lee KS; Lee HW; Choo MS; Paick JS; Lee JG; Seo JT; Lee JZ; Lee YS; Yoon H; Park CH; Na YG; Jeong YB; Lee JB; Park WH
    BJU Int; 2010 Jun; 105(11):1565-70. PubMed ID: 19912183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised, prospective double-blind, propiverine-controlled trial of imidafenacin in patients with overactive bladder.
    Park C; Park J; Choo MS; Kim JC; Lee JG; Lee JZ; Lee KS; Kim DY; Lee SJ; Seo JT
    Int J Clin Pract; 2014 Feb; 68(2):188-96. PubMed ID: 24373019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic effect of propiverine hydrochloride on mixed-type urinary incontinence in women: The Female Urgency and Stress Urinary Incontinence Study of Propiverine Hydrochloride trial.
    Minagawa T; Gotoh M; Yokoyama O; Sugaya K; Yamanishi T; Kawahara K; Kaga K; Kikuchi T; Nishizawa O;
    Int J Urol; 2018 May; 25(5):486-491. PubMed ID: 29651806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study.
    Lee KS; Choo MS; Kim DY; Kim JC; Kim HJ; Min KS; Lee JB; Jeong HJ; Lee T; Park WH
    J Urol; 2005 Oct; 174(4 Pt 1):1334-8. PubMed ID: 16145414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.
    Yamaguchi O; Marui E; Kakizaki H; Itoh N; Yokota T; Okada H; Ishizuka O; Ozono S; Gotoh M; Sugiyama T; Seki N; Yoshida M;
    BJU Int; 2007 Sep; 100(3):579-87. PubMed ID: 17669143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between the Overactive Bladder questionnaire (OAB-q) and urodynamic data of Parkinson disease patients affected by neurogenic detrusor overactivity during antimuscarinic treatment.
    Palleschi G; Pastore AL; Stocchi F; Bova G; Inghilleri M; Sigala S; Carbone A
    Clin Neuropharmacol; 2006; 29(4):220-9. PubMed ID: 16855424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequent nocturia episodes, a suboptimal response to treatment, and small bladder capacity predict the need for persistent antimuscarinic therapy or re-treatment after discontinuation of antimuscarinics in female overactive bladder.
    Hsiao SM; Chang TC; Chen CH; Wu WY; Lin HH
    Menopause; 2017 Jan; 24(1):100-104. PubMed ID: 27648660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
    Wagg A; Wyndaele JJ; Sieber P
    Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of a randomized, double-blind, active-controlled clinical trial with propiverine extended release 30 mg in patients with overactive bladder.
    Leng J; Liao L; Wan B; Du C; Li W; Xie K; Shen Z; Xu Z; Wu S; Fang Z; Ma L; Han S; Feustel C; Yang Y; Madersbacher H
    BJU Int; 2017 Jan; 119(1):148-157. PubMed ID: 27087507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined low-dose antimuscarinics for refractory detrusor overactivity in children.
    Fahmy A; Youssif M; Rhashad H; Mokhless I; Mahfouz W
    J Pediatr Urol; 2016 Aug; 12(4):219.e1-5. PubMed ID: 27282551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE).
    Cardozo L; Amarenco G; Pushkar D; Mikulas J; Drogendijk T; Wright M; Compion G;
    BJU Int; 2013 May; 111(5):804-10. PubMed ID: 23294801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
    Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
    BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
    Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
    Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study.
    Yokoyama T; Uematsu K; Watanabe T; Sasaki K; Kumon H; Nagai A;
    Scand J Urol Nephrol; 2009; 43(4):307-14. PubMed ID: 19396723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms.
    Serels SR; Toglia MR; Forero-Schwanhaeuser S; He W
    Curr Med Res Opin; 2010 Oct; 26(10):2277-85. PubMed ID: 20707767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
    Garely AD; Lucente V; Vapnek J; Smith N
    Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for the failure of antimuscarinic treatment with solifenacin in women with overactive bladder.
    Serati M; Braga A; Siesto G; Sorice P; Cattoni E; Uccella S; Cromi A; Salvatore S; Ghezzi F
    Urology; 2013 Nov; 82(5):1044-8. PubMed ID: 24054438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined Tolterodine and Vaginal Estradiol Cream for Overactive Bladder Symptoms After Randomized Single-Therapy Treatment.
    Ellington DR; Szychowski JM; Malek JM; Gerten KA; Burgio KL; Richter HE
    Female Pelvic Med Reconstr Surg; 2016; 22(4):254-60. PubMed ID: 26945271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Adherence of Flexibly Adding on a Second Antimuscarinic Agent for Patients with Refractory Overactive Bladder.
    Wang CC; Jiang YH; Kuo HC
    Low Urin Tract Symptoms; 2017 Jan; 9(1):27-32. PubMed ID: 28120445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.